GeneDx price target raised to $24 from $14 at TD Cowen

TD Cowen raised the firm’s price target on GeneDx to $24 from $14 and keeps a Buy rating on the shares. The firm said the company’s turnaround story is well underway following a strong beat and raise as momentum continues to build from revenue to cash burn and Cowen now sees a clear path to profitability in 2024.